Kyntra Bio (KYNB) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $118.0 million.
- Kyntra Bio's Cash & Equivalents fell 994.48% to $118.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.0 million, marking a year-over-year decrease of 994.48%. This contributed to the annual value of $50.5 million for FY2024, which is 5559.6% down from last year.
- As of Q3 2025, Kyntra Bio's Cash & Equivalents stood at $118.0 million, which was down 994.48% from $23.4 million recorded in Q2 2025.
- Kyntra Bio's Cash & Equivalents' 5-year high stood at $433.5 million during Q1 2021, with a 5-year trough of $23.4 million in Q2 2025.
- Over the past 5 years, Kyntra Bio's median Cash & Equivalents value was $152.6 million (recorded in 2023), while the average stood at $161.9 million.
- In the last 5 years, Kyntra Bio's Cash & Equivalents surged by 25662.06% in 2021 and then crashed by 8339.4% in 2025.
- Kyntra Bio's Cash & Equivalents (Quarter) stood at $171.2 million in 2021, then dropped by 9.07% to $155.7 million in 2022, then decreased by 26.98% to $113.7 million in 2023, then tumbled by 55.6% to $50.5 million in 2024, then skyrocketed by 133.7% to $118.0 million in 2025.
- Its Cash & Equivalents was $118.0 million in Q3 2025, compared to $23.4 million in Q2 2025 and $33.6 million in Q1 2025.